CHATSWORTH, Calif., May 17, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), today announced that it will hold its 2011 Annual Meeting of Stockholders on Friday, May 20, 2011 at 10:00 a.m. Pacific Time. The meeting will be held at the Company's corporate headquarters located at 9158 Eton Avenue, Chatsworth, California.
Shareholders of record at the close of business on April 5, 2011 are entitled to vote, either in person or by Proxy, on the following proposals to come before the meeting as presented in the Company's Proxy Statement, which was mailed to stockholders on April 18, 2011: To elect nine Directors to hold office until the 2012 annual meeting, to approve the IRIS International, Inc. 2011 Omnibus Incentive Plan, to hold an advisory vote on executive compensation, to hold an advisory vote on the frequency of the advisory vote on executive compensation, and to ratify the selection of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2011.
All shareholders who have not yet voted their shares are encouraged to do so in favor of the Company's proposals. If your shares are held in "Street" name, you must obtain a Proxy from the holder of record in order to vote at the Annual Meeting. Please mark, date, sign and return the Proxy as soon as possible.
Further information can be found in the Company's Proxy Statement filed with the U.S. Securities and Exchange Commission on April 14, 2011, or on the IRIS web site at .
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,100 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and body fluids. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit .
CONTACT: Cesar Garcia Chairman, President and Chief Executive Officer IRIS International, Inc. 818-527-7000 -or- Ron Stabiner, The Wall Street Group, Inc. 212-888-4848